BOLD / Boundless Bio, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

POWER OF ATTORNEY

EXHIBIT 2 EXHIBIT 2 POWER OF ATTORNEY Know all by these presents, that Astellas US Holding, Inc.

TSHA / Taysha Gene Therapies Inc / Audentes Therapeutics, Inc. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 TAYSHA GENE THERAPIES, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 877619106 (CUSIP Number) Audentes Therapeutics, Inc. 600 California Street 17th Floor San Francisco, CA 94108 Attention: President (415) 818-1005 With a copy

POWER OF ATTORNEY

EXHIBIT 3 EXHIBIT 3 POWER OF ATTORNEY Know all by these presents, that Audentes Therapeutics, Inc.

JOINT FILING AGREEMENT

EXHIBIT 4 EXHIBIT 4 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.

POWER OF ATTORNEY

EXHIBIT 1 EXHIBIT 1 POWER OF ATTORNEY Know all by these presents, that Astellas Pharma Inc.

BOLD / Audentes Therapeutics, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Audentes Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2019 Date of Event Which

BOLD / Audentes Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

BOLD / Audentes Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

BOLD / Audentes Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Audentes Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 05070R104 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b)

BOLD / Audentes Therapeutics, Inc. / BlackRock Inc. Passive Investment

us05070r1041020420.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Audentes Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 05070R104 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

BOLD / Audentes Therapeutics, Inc. 15-12B - - 15-12B

15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-37833 Audentes Therapeutics, Inc. (Exact name of registrant as speci

ALPMF / Astellas Pharma, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Co

BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2020 Audentes Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commi

BOLD / Audentes Therapeutics, Inc. POSASR - - POSASR

POSASR As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

Amended and Restated Certificate of Incorporation of Audentes Therapeutics, Inc.

EX-3.1 Exhibit 3.1 SIXTH RESTATED CERTIFICATE OF INCORPORATION OF AUDENTES THERAPEUTICS, INC. * * * ARTICLE I NAME The name of the Corporation is Audentes Therapeutics, Inc. ARTICLE II REGISTERED OFFICE AND REGISTERED AGENT The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, County of New Castle, Delaware 1

Amended and Restated Bylaws of Audentes Therapeutics, Inc.

EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF AUDENTES THERAPEUTICS, INC. a Delaware Corporation (hereinafter referred to as the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and the registered agent of the Corporation are as set forth in the Certificate of Incorporation. Section 2. Other Offices. The Corporation may also have offices at such other

Astellas Completes Acquisition of Audentes Therapeutics

EX-99.1 Exhibit 99.1 Press Release Astellas Completes Acquisition of Audentes Therapeutics - Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus - Natalie C. Holles appointed President and Chief Executive Officer of Audentes T

BOLD / Audentes Therapeutics, Inc. POS AM - - POS AM

POS AM As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

BOLD / Audentes Therapeutics, Inc. POS AM - - POS AM

POS AM As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

BOLD / Audentes Therapeutics, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title o

BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No.

BOLD / Audentes Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

BOLD / Audentes Therapeutics, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title o

ALPMF / Astellas Pharma, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Co

BOLD / Audentes Therapeutics, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title o

ALPMF / Astellas Pharma, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Comm

Offer to Purchase All Outstanding Shares of Common Stock AUDENTES THERAPEUTICS, INC. $60.00 PER SHARE, Net in Cash Pursuant to the Offer to Purchase dated December 16, 2019 ASILOMAR ACQUISITION CORP., an indirect, wholly-owned subsidiary ASTELLAS PHA

Exhibit (a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of AUDENTES THERAPEUTICS, INC.

* * *

EX-99.(E)(13) Exhibit (e)(13) November 30, 2019 Edward Conner, M.D. Re: RETENTION AGREEMENT Dear Ed: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement

ALPMF / Astellas Pharma, Inc. SC TO-T - - SC TO-T

SC TO-T 1 d837696dsctot.htm SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offer

Audentes Therapeutics, Inc. Tax Reimbursement and Bonus Plan, dated December 10, 2019 (Incorporated by reference to Exhibit (e)(15) to the Registrant’s Solicitation/Recommendation Statement on Schedule 14D-9 filed on December 16, 2019).

EX-99.(E)(15) Exhibit (e)(15) AUDENTES THERAPEUTICS, INC. TAX REIMBURSEMENT AND BONUS PLAN This Tax Reimbursement and Bonus Plan (the “Plan”) was adopted by the Compensation Committee of the Board of Directors of Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), effective as of December 10, 2019 (the “Effective Date”). 1. Purpose. The purpose of the Plan is to (a) reimburse the

Letter of Transmittal to Tender Shares of Common Stock of Audentes Therapeutics, Inc. $60.00 Per Share, Net in Cash Pursuant to the Offer to Purchase dated December 16, 2019 Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas

Exhibit (a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of Audentes Therapeutics, Inc.

Offer To Purchase All Outstanding Shares of Common Stock AUDENTES THERAPEUTICS, INC. $60.00 Per Share, Net in Cash ASILOMAR ACQUISITION CORP., an indirect, wholly-owned subsidiary of ASTELLAS PHARMA INC.

Exhibit (a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of AUDENTES THERAPEUTICS, INC.

BOLD / Audentes Therapeutics, Inc. SC 14D9 - - SC 14D9

SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Offer to Purchase All Outstanding Shares of Common Stock AUDENTES THERAPEUTICS, INC. $60.00 PER SHARE, NET IN CASH Pursuant to the Offer to Purchase dated December 16, 2019 ASILOMAR ACQUISITION CORP., an indirect, wholly-owned subsidiary ASTELLAS PHA

Exhibit (a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of AUDENTES THERAPEUTICS, INC.

* * *

EX-99.(E)(14) Exhibit (e)(14) November 30, 2019 Eric B. Mosbrooker Re: RETENTION AGREEMENT Dear Eric: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement

[Signature Page Follows]

EX-99.(d)(2) Exhibit (d)(2) October 15, 2019 CONFIDENTIAL Astellas Pharma Inc. 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan Ladies and Gentlemen: In connection with discussions between Astellas Pharma Inc. (“you”) and Audentes Therapeutics, Inc. (the “Company” and collectively with you, the “parties”) of a possible negotiated acquisition transaction (a “Transaction”), the Company may f

Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes

Exhibit (a)(1)(L) Exhibit (a)(1)(L) Press Release Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes TOKYO, December 16, 2019 - Astellas Pharma Inc.

Notice of Offer to Purchase All Outstanding Shares of Common Stock AUDENTES THERAPEUTICS, INC. at $60.00 Per Share, Net in Cash ASILOMAR ACQUISITION CORP., an indirect, wholly-owned subsidiary ASTELLAS PHARMA INC.

Exhibit (a)(1)(K) Exhibit (a)(1)(K) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

ALPMF / Astellas Pharma, Inc. SC TO-C - - SC TO-C

SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.00001

- 1 -

EX-99.1 Exhibit 99.1 Cover Document to be filed Extraordinary Report Filing to Director-General of the Kanto Local Finance Bureau Date of filing December 9, 2019 Company name (Japanese) アステラス製薬株式会社 (Asuterasu Seiyaku Kabushiki-Kaisha) Company name (English) Astellas Pharma Inc. Title and name of representative President and CEO: Kenji Yasukawa Location of head office 2-5-1, Nihonbashi-Honcho, Chuo

ALPMF / Astellas Pharma, Inc. SC TO-C - - SC TO-C

SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.00001

Summary Transcript of Telephone Conference Call December 3, 2019

EX-99.1 Exhibit 99.1 Summary Transcript of Telephone Conference Call December 3, 2019 Introduction Thank you for joining Astellas’ telephone conference despite your busy schedule. We are holding a conference regarding the acquisition of Audentes, announced this morning. My name is Stig Ogata from Public Relations, the moderator of this telephone conference. Let me introduce the speakers for today.

This document contains “forward-looking statements” relating to the acquisition of Audentes by Astellas. Such forward-looking statements include, but are not limited to, the ability of Audentes and Astellas to complete the transactions contemplated b

EX-99.3 Acquisition of Audentes Establishing a leading position in gene therapy Naoki Okamura Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Astellas Pharma Inc. December 3, 2019 Exhibit 99.3 This document contains “forward-looking statements” relating to the acquisition of Audentes by Astellas. Such forward-looking statements includ

ALPMF / Astellas Pharma, Inc. SC TO-C - - SC TO-C

SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.00001

External Stakeholder Q&A

EX-99.4 Exhibit 99.4 External Stakeholder Q&A General 1. What has been announced? • We have announced today that Audentes has entered into a definitive agreement to be acquired by Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. Both Boards of Directors unanimously approved the planned acquisition. • Under the agreement, Astellas will acquire Audentes for $60.00 per share i

Retention Agreement between the Company and Matthew Patterson, dated November 30, 2019

EX-10.1 Exhibit 10.1 November 30, 2019 Matthew Patterson Re: RETENTION AGREEMENT Dear Matt: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement during a

Good afternoon team BOLD!

EX-99.1 Exhibit 99.1 Good afternoon team BOLD! Just a moment ago we announced the very exciting news that Audentes has entered into a definitive agreement to be acquired by Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. The press release is enclosed for your reference. This news is the ultimate recognition of the phenomenal work that our team has done to make the Audentes

December 2, 2019

EX-99.4 5 d599615dex994.htm EX-99.4 Exhibit 99.4 December 2, 2019 Dear Audentes Colleagues: On behalf of the more than 16,000 employees of the Astellas group worldwide, it is a great pleasure for me to share with you how excited all of us are about today’s announcement that Astellas and Audentes have reached an agreement to merge and work together in support of patients moving forward. We highly v

December 2, 2019

EX-99.5 Exhibit 99.5 December 2, 2019 Dear XLMTM Patient Community, I am writing to share with you some news announced earlier today, that we have entered into a definitive merger agreement with Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. The press release, sharing the details of the acquisition, can be found here: https://audentestx.gcs-web.com/news-releases/news-rele

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics and Plans to Commence Tender Offer - A Major Step to Establishing a Leading Position in Gene Therapy - - AT132, Audentes’ Lead Program, in Phase I/II Clinical Stage - - Transa

EX-99.2 Exhibit 99.2 December 3, 2019 Company Name Astellas Pharma Inc. Representative Kenji Yasukawa, President and CEO (Stock Code: 4503, Tokyo Stock Exchange First Section) (URL: https://www.astellas.com/en) Fiscal Year End March Contact for Inquiries Stig Ogata, Vice President, Corporate Communications (Tel: 03-3244-3201) Astellas Enters into Definitive Agreement to Acquire Audentes Therapeuti

December 3, 2019

EX-99.2 Exhibit 99.2 December 3, 2019 Dear Astellas Colleagues, We are absolutely delighted with today’s news and excited to join together with Astellas. We have a great deal of respect and admiration for your organization, the vision and the strategy you have set, and we look forward to the opportunities that will be created by bringing our two great companies together. Audentes is a passionate a

Agreement and Plan of Merger, dated as of December 2, 2019, by and among Astellas Pharma Inc., Asilomar Acquisition Corp., and Audentes Therapeutics, Inc.*

EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 2, 2019 AMONG ASTELLAS PHARMA INC., ASILOMAR ACQUISITION CORP. AND AUDENTES THERAPEUTICS, INC. Table of Contents Page ARTICLE 1 DEFINITIONS; INTERPRETATION 2 SECTION 1.1. Definitions 2 SECTION 1.2. Interpretation 12 ARTICLE 2 THE OFFER 13 SECTION 2.1. The Offer 13 SECTION 2.2. Company Action 15 ARTICLE 3 THE MER

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commi

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

EX-99.1 Exhibit 99.1 Press Release Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics • Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company • Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufactu

BOLD / Audentes Therapeutics, Inc. SC14D9C - - SC14D9C

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title of Class of Securitie

Employee Q&A

EX-99.3 Exhibit 99.3 Employee Q&A 1. What was announced today? • We have announced today that Audentes has entered into a definitive agreement to be acquired by Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. Both Boards of Directors unanimously approved the planned acquisition. • Under the agreement, Astellas will acquire Audentes for $60.00 per share in cash representing

Retention Agreement between the Company and Natalie Holles, dated November 30, 2019

EX-10.2 4 d841784dex102.htm EX-10.2 Exhibit 10.2 November 30, 2019 Natalie Holles Re: RETENTION AGREEMENT Dear Natalie: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your co

Template Email to partners/vendors

EX-99.6 Exhibit 99.6 Template Email to partners/vendors Template cover email for communications to other partners/vendors: Dear [xxx], I am writing to share with you some news announced earlier today, that we have entered into a definitive agreement for Astellas to acquire Audentes. The press release, sharing the details of the acquisition, can be found here: https://audentestx.gcs-web.com/news-re

Retention Agreement between the Company and Thomas Soloway, dated November 30, 2019

EX-10.3 Exhibit 10.3 November 30, 2019 Thomas Soloway Re: RETENTION AGREEMENT Dear Tom: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement during a rete

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

EX-99.1 Exhibit 99.1 Press Release Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics • Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company • Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufactu

Evolving how we create VALUE with the acquisition of Audentes

EX-99.5 Exhibit 99.5 Evolving how we create VALUE with the acquisition of Audentes Dear Astellas Colleagues: I am very pleased to announce that Astellas and Audentes Therapeutics, Inc., an innovative biotechnology company located in San Francisco, California, have entered into an agreement for Astellas to acquire Audentes. The addition of Audentes’ talent and exciting clinical pipeline of gene the

BOLD / Audentes Therapeutics, Inc. / FMR LLC / Fidelity Passive Investment

SCHEDULE 13G Amendment No. 5 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05070R104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 1,058,816 Item 8: 0 Item 9: 1,058,816 Item 11: 2.3

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Juris

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update - BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020 - Continued progress in Pompe Disease,

EX-99.1 2 bold20191107ex991.htm EXHIBIT 99.1 Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update - BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020 - Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND o

2016 Equity Incentive Plan

Exhibit 10.1 AUDENTES THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Com

2018 Equity Inducement forms of award agreements

Exhibit 10.3 AUDENTES THERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Awar

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37

2016 Equity Incentive forms of award agreements

Exhibit 10.2 AUDENTES THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Audentes Therapeutics, Inc. 2016 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Award

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisd

Exhibit 99.2 The ASPIRO Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings James J. Dowling, MD, PhD Associate Professor of Molecular Genetics University of Toronto Perry B. Shieh, Nancy Kun

EX-99.2 12 exhibit992.htm EXHIBIT 99.2 Exhibit 99.2 The ASPIRO Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings James J. Dowling, MD, PhD Associate Professor of Molecular Genetics University of Toronto Perry B. Shieh, Nancy Kuntz, Carsten G. Bönnemann, Wolfgang Müller-Felber, Michael W. Lawlor, Laurent Servais, Barbara Smith, Mo Noursal

Exhibit 99.1 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society - First seven

EX-99.1 8 exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society - First seven treated patients now ventilator independent and able to rise to a standing position or walk - Continued signific

BOLD / Audentes Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Amendment No )* Under the Securities Exchange Act of 1934 Audentes Therapeutics, Inc. (Name of Issuer) Common Shares, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) September 4, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K/A ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdi

Separation Letter Agreement, executed June 25, 2019, by and between the Registrant and Suyash Prasad

Exhibit 10.2 [Audentes Letterhead] June 24, 2019 Dr. Suyash Prasad Re: Terms of Separation Dear Suyash: This letter agreement (this “Agreement”) confirms the agreement between you and Audentes Therapeutics, Inc. (the “Company”) concerning the terms of your separation from the Company and offers you the separation compensation specified herein in exchange for your general release of claims, covenan

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 A

Separation Letter Agreement, executed May 30, 2019, by and between the Registrant and John Gray

Exhibit 10.1 [Audentes Letterhead] May 24, 2019 John Gray, Ph.D. Re: Terms of Separation Dear John: This letter agreement (this “Agreement”) confirms the agreement between you and Audentes Therapeutics, Inc. (the “Company”) concerning the terms of your separation from the Company and offers you the separation compensation specified herein in exchange for your general release of claims, covenant no

Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Commenced enrollment of 8 patients into an ASPIRO pivotal expansion cohort to confirm the safety and efficacy profile of AT132 for the treatment of X-

a20190806q22019eprfinal Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Commenced enrollment of 8 patients into an ASPIRO pivotal expansion cohort to confirm the safety and efficacy profile of AT132 for the treatment of X-linked myotubular myopathy (XLMTM) at dose of 3x1014 vg/kg - Biologics License Application (BLA) submission for AT132 planned

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 q219epr-8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-160617

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdic

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdict

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdict

BOLD / Audentes Therapeutics, Inc. S-8 S-8

As filed with the Securities and Exchange Commission on May 10, 2019 Registration No.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833

Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update ‐ Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM ‐ On track to submit updated ASPIRO

EX-99.1 2 ex991q12019eprfinal.htm EXHIBIT 99.1 Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update ‐ Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM ‐ On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second quarter of 2019 and to provide update on

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdicti

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy

EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy - New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Signi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commission

Disclosures Principal Investigator in the INCEPTUS and ASPIRO XLMTM clinical trials Advisory boards Audentes, Sarepta, Roche, Avexis, Biogen Speakers’ bureau Biogen, Alexion, CSL Behring, Grifols

ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings Perry Shieh, MD PhD Associate Professor of Neurology, University of California Los Angeles Exhibit 99.

BOLD / Audentes Therapeutics, Inc. DEFA14A DEFA14A NOTICE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

BOLD / Audentes Therapeutics, Inc. DEF 14A DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy

EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy - Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2019 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commissi

Form of Restricted Stock Unit Award Agreement for 2018 Equity Inducement Plan.

EX-10.5B 2 bold-ex105b144.htm EX-10.5B Exhibit 10.5b AUDENTES THERAPEUTICS, INC. 2018 Equity INDUCEMENT Plan NOTICE OF RESTRICTED STOCK UNIT AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of t

BOLD / Audentes Therapeutics, Inc. 10-K (Annual Report)

i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37833 Audentes Therapeutics, I

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2019 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Comm

Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA

Exhibit 99.1 Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA submission pathways in the third quarter of 2019 On track to submit an Investigational New Drug (IND) application for AT845 for Pompe Di

BOLD / Audentes Therapeutics, Inc. / Partner Fund Management, L.P. - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Audentes Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2018 Date of Event Which

BOLD / Audentes Therapeutics, Inc. / Redmile Group, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Joint Filing Agreement

EX-99.1 2 tv513365ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.00001 pa

BOLD / Audentes Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Audentes Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 05070R104 (CUSIP NUMBER) December 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S

BOLD / Audentes Therapeutics, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G HOLDINGS REPORT AMENDMENT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

BOLD / Audentes Therapeutics, Inc. / FMR LLC / Fidelity Passive Investment

SCHEDULE 13G Amendment No. 4 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05070R104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,700 Item 6: 0 Item 7: 3,151,884 Item 8: 0 Item 9: 3,151,884 Item 11:

BOLD / Audentes Therapeutics, Inc. / 5AM VENTURES III, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number

BOLD / Audentes Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

BOLD / Audentes Therapeutics, Inc. / BlackRock Inc. Passive Investment

us05070r1041020719.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Audentes Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 05070R104 - (CUSIP Number) December 31, 2018 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

Executive Employment Agreement, effective September 19, 2018, by and between the Registrant and Natalie Holles

Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and Natalie Holles (the “Executive”). This Agreement is effective as of September , 2018 (the “Effective Date”). This Agreement supersedes and replaces in its entirety the Executive Employment Agreements dated February 14, 2018 and Ju

First Amendment dated September 30, 2018, to Net Commercial Lease, effective June 1, 2017, by and between the Registrant and JCN Partners.

EX-10.2 3 bold-ex102120.htm EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO NET COMMERCIAL LEASE This First Amendment to Net Commercial Lease (this “Amendment”) dated September 30, 2018, for reference purposes only, is by and between JCN PARTNERS, a California limited partnership (“Lessor”), and AUDENTES THERAPEUTICS, INC., a Delaware corporation (“Lessee”), with reference to the following facts: WHEREAS,

Net Commercial Lease, dated August 15, 2018, by and between the Registrant and JCN Partners.

Exhibit 10.1 NET COMMERCIAL LEASE This Net Commercial Lease (this “Lease”) dated August 15, 2018, for reference purposes only, is by and between JCN PARTNERS, a California limited partnership (“Lessor”), and AUDENTES THERAPEUTICS, INC., a Delaware corporation (“Lessee”). IT IS HEREBY AGREED: Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the premises described in Paragraph 1

BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Thera

BOLD / Audentes Therapeutics, Inc. S-8

S-8 1 bold-s8.htm S-8 As filed with the Securities and Exchange Commission on November 6, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-1606174 (State or other jurisdiction of (I.R.S. Emp

2018 Equity Inducement Plan and forms of award agreements.

Exhibit 99.2 Audentes Therapeutics, INC. 2018 EQUITY InDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commi

Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update - Completed Cohort 2 enrollment in ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-linked Myotubular Myopathy - Plan interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in Q4 2018 to di

BOLD / Audentes Therapeutics, Inc. / Partner Fund Management, L.P. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) October 17, 2018 Date of Event Which Req

JOINT FILING AGREEMENT

EX-99.1 2 tv505647ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Audentes Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exch

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis

Audentes Therapeutics Announces Pricing of Public Offering of Common Stock

EX-99.1 4 bold-ex9917.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, Oct. 10, 2018 / PRNewswire/ - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the

1.1Underwriting Agreement dated October 10, 2018

Exhibit 1.1 Audentes Therapeutics, Inc. (a Delaware corporation) 5,200,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: October 10, 2018 Audentes Therapeutics, Inc. (a Delaware corporation) 5,200,000 Shares of Common Stock UNDERWRITING AGREEMENT October 10, 2018 Merrill Lynch, Pierce, Fenner & Smith Incorporated J.P.Morgan Securities LLC Cowen and Company, LLC as Representatives of the sev

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee(2) Common stock, $0.00001 par

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224020 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee(2) Common stock, $0.00001 par value per share 5,980,000 $29.00 $173,420,000 $21,018.50 (1) Inc

BOLD / Audentes Therapeutics, Inc. / FMR LLC / Fidelity Passive Investment

SCHEDULE 13G Amendment No. 3 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05070R104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,885 Item 6: 0 Item 7: 3,896,391 Item 8: 0 Item 9: 3,896,391 Item 11:

Subject to Completion Preliminary Prospectus Supplement dated October 9, 2018

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224020 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitt

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis

Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions

EX-99.1 2 bold-ex9916.htm EX-99.1 ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Preliminary Safety and Efficacy Findings Exhibit 99.1 Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainti

LETTER

September 7, 2018 Thomas Soloway Chief Financial Officer Audentes Therapeutics, Inc.

BOLD / Audentes Therapeutics, Inc. TEXT-EXTRACT

September 7, 2018 Thomas Soloway Chief Financial Officer Audentes Therapeutics, Inc.

BOLD / Audentes Therapeutics, Inc. / FMR LLC / Fidelity Passive Investment

SCHEDULE 13G Amendment No. 2 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05070R104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,885 Item 6: 0 Item 7: 3,621,693 Item 8: 0 Item 9: 3,621,693 Item 11:

BOLD / Audentes Therapeutics, Inc. 10-Q/A (Quarterly Report)

10-Q/A 1 bold-10qa20180331.htm 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from

BOLD / Audentes Therapeutics, Inc. CORRESP

August 10, 2018 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-3720 Re: Audentes Therapeutics, Inc.

BOLD / Audentes Therapeutics, Inc. 10-K/A (Annual Report)

10-K/A 1 bold-10ka20171231.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIO

Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy

EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy - Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western bl

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commiss

BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeuti

LETTER

August 6, 2018 Thomas Soloway Chief Financial Officer Audentes Therapeutics, Inc. 600 California Street, 17th Floor San Francisco, CA 94108 Re: Audentes Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed March 9, 2018 File No. 001-37833 Dear Mr. Soloway: We have limited our review of your filing to the financial statements and related disclosures and have the following

BOLD / Audentes Therapeutics, Inc. TEXT-EXTRACT

August 6, 2018 Thomas Soloway Chief Financial Officer Audentes Therapeutics, Inc. 600 California Street, 17th Floor San Francisco, CA 94108 Re: Audentes Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed March 9, 2018 File No. 001-37833 Dear Mr. Soloway: We have limited our review of your filing to the financial statements and related disclosures and have the following

BOLD / Audentes Therapeutics, Inc. 8-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commissio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commissio

Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy

Exhibit 99.1 Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy - Significant improvements in neuromuscular and respiratory function at 24-week timepoint - Encouraging initial efficacy observed at four-week timepoint in Cohort 1 expansion patients - Patient 1 has achieved ventilator indepen

Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes

EX-99.2 3 bold-ex9926.htm EX-99.2 X-Linked Myotubular Myopathy (XLMTM) ASPIRO Phase 1/2 Gene Therapy Trial In XLMTM: Interim Safety And Efficacy Findings Exhibit 99.2 Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assump

BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeut

Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update - Completed dosing of three additional patients as an expansion of the first dose cohort of ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) - Plan to report additional interim data from ASPIRO during an oral presentation at the 21st A

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis

BOLD / Audentes Therapeutics, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

BOLD / Audentes Therapeutics, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

BOLD / Audentes Therapeutics, Inc. CT ORDER

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A #0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G (.+094P C$+ P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;," P(#8Q,B W.3)= M+TUE9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@." P(

Statement of Computation of Ratio of Earnings to Fixed Charges

EX-12.1 Exhibit 12.1 AUDENTES THERAPEUTICS, INC. Computation of Ratio of Earnings to Fixed Charges Year Ended December 31, 2013 2014 2015 2016 2017 (in thousands) Earnings before fixed charges: Net loss $ (3,054 ) $ (10,819 ) $ (26,458 ) $ (59,668 ) $ (90,238 ) Fixed charges: Estimated interest expense within rental expense $ 10 $ 84 $ 490 $ 852 $ 986 Deficiency of earnings: $ (3,064 ) $ (10,904 )

Form of debt security

EX-4.4 3 d556584dex44.htm EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] AUDENTES THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF I

Form of indenture

EX-4.5 4 d556584dex45.htm EX-4.5 Exhibit 4.5 AUDENTES THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 3 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS

Sales Agreement, dated as of March 29, 2018, by and between the Registrant and Cowen and Company, LLC

EX-1.2 2 d556584dex12.htm EX-1.2 Exhibit 1.2 AUDENTES THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT March 29, 2018 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of

BOLD / Audentes Therapeutics, Inc. S-3ASR

S-3ASR 1 d556584ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 29, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Audentes Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1606174 (State or other

Fourth Amendment to Exclusive License and Collaboration Agreement, effective December 20, 2017, by and between the Registrant and The Trustees of the University of Pennsylvania.

EX-10.24 4 bold-ex1024122.htm EX-10.24 EXHIBIT 10.24 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. FOURTH AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This FOURTH AMENDMENT (“Fourth Amendmen

Form of Executive Employment Agreement

Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and (the “Executive”). This Agreement is effective as of , 20 (the “Effective Date”). [This Agreement supersedes and replaces in its entirety the dated , between Executive and the Company.]1 In consideration of the promises and the te

First Amendment to License Agreement, dated November 3, 2017, by and between the Registrant and REGENXBIO Inc. (relating to CPVT).

EXHIBIT 10.18 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. FIRST AMENDMENT TO License Agreement This FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into as of November 3, 2017 (“Firs

Power of Attorney. (See signature page thereto.)

i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37833 Audentes Ther

Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update

EX-99.1 2 bold-ex99117.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update - Announced positive interim data in the first three patients dosed in ASPIRO, the Phase 1/2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM). Plan to dose three additional patients in the first cohort of ASPIRO and to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commissi

BOLD / Audentes Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G 1 bold13gdec17.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Audentes Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 05070R104 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule

BOLD / Audentes Therapeutics, Inc. / Sofinnova Venture Partners IX, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tv485881sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No.1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities)

BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment

SC 13G/A 1 e617661sc13ga-audentes.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities

BOLD / Audentes Therapeutics, Inc. / ORBIMED ADVISORS LLC - 13G/A (Passive Investment)

SC 13G/A 1 bold123117a1.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

BOLD / Audentes Therapeutics, Inc. / Versant Side Fund IV, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 a18-59241sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CU

BOLD / Audentes Therapeutics, Inc. / Adage Capital Partners GP LLC - AUDENTES THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t

BOLD / Audentes Therapeutics, Inc. / FMR LLC / Fidelity Passive Investment

SCHEDULE 13G Amendment No. 1 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05070R104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 30,000 Item 6: 0 Item 7: 4,411,633 Item 8: 0 Item 9: 4,411,633 Item 11

BOLD / Audentes Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) January 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

BOLD / Audentes Therapeutics, Inc. / 5AM VENTURES III, L.P. - SC 13G/A (Passive Investment)

SC 13G/A 1 a18-56242sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Clas

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37833 46-1606174 (State or other jurisdiction of incorporation) (Commi

Underwriting Agreement dated January 24, 2018

EX-1.1 2 d530511dex11.htm EX-1.1 Exhibit 1.1 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) 5,750,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 24, 2018 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) 5,750,000 Shares of Common Stock UNDERWRITING AGREEMENT January 24, 2018 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC Leerink Partners LLC a

Audentes Therapeutics Announces Pricing of Public Offering of Common Stock

Exhibit 99.1 Audentes Therapeutics Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, Jan. 24, 2018 / PRNewswire/ ? Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public

5,750,000 Shares Common Stock

424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-219797 PROSPECTUS SUPPLEMENT (To prospectus dated August 23, 2017) 5,750,000 Shares Common Stock We are offering 5,750,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?BOLD.? The last reported sale price of our common stock on The Nasdaq Global Market on January 24,

BOLD / Audentes Therapeutics, Inc. S-3MEF

S-3MEF As filed with the Securities and Exchange Commission on January 24, 2018 Registration No.

BOLD / Audentes Therapeutics, Inc. 8-K (Current Report)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (C

Subject to Completion Preliminary Prospectus Supplement dated January 23, 2018

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-219797 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Su

BOLD / Audentes Therapeutics, Inc. 8-K (Current Report)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Co

Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions

EX-99.2 ASPIRO Study Interim data as of December 21, 2017 Exhibit 99.2 Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual act

Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy - Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale - S

EX-99.1 2 d710862dex991.htm EX-99.1 Exhibit 99.1 Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy - Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale - Significant improvements in respiratory function as assessed by maximal inspiratory pressure (MIP) - M

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (

BOLD / Audentes Therapeutics, Inc. S-8

bold-s8.htm As filed with the Securities and Exchange Commission on November 14, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-1606174 (State or other jurisdiction of (I.R.S. Employer inc

BOLD / Audentes Therapeutics, Inc. 8-K (Current Report)

bold-8k20171114.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of

Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

bold-ex9918.htm Exhibit 99.1 Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - Completed enrollment of the first dose cohort of ASPIRO, the Phase 1/2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM) - AT132 has been well-tolerated by all patients with no significant treatment-related safety signals to date - Plan to report preli

BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Thera

BOLD / Audentes Therapeutics, Inc. / FMR LLC / Fidelity Passive Investment

SCHEDULE 13G Amendment No. 0 AUDENTES THERAPEUTICS INC COMMON STOCK Cusip #05070R104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05070R104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 30,000 Item 6: 0 Item 7: 3,272,598 Item 8: 0 Item 9: 3,272,598 Item 11

Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes

bold-ex994487.pptx.htm Audentes Corporate Overview September 27, 2017 Exhibit 99.4 Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual act

Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy Preliminary data from ASPIRO, the Phase 1/2 study of AT132, expected to be available in the fourth quarter

bold-ex992639.htm Exhibit 99.2 Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy Preliminary data from ASPIRO, the Phase 1/2 study of AT132, expected to be available in the fourth quarter of 2017 SAN FRANCISCO, September 27, 2017 / PRNewswire/ - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology c

CONFIDENTIAL Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties

bold-ex993798.pptx.htm AT132 for X-Linked Myotubular Myopathy INCEPTUS Study Interim Results Exhibit 99.3 CONFIDENTIAL Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances t

Audentes Therapeutics 8-K (Current Report/Significant Event)

bold-8k20170921.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy Preliminary data from ASPIRO expected to be available in the fourth quarter of 2017

EX-99.1 2 bold-ex991488.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy Preliminary data from ASPIRO expected to be available in the fourth quarter of 2017 SAN FRANCISCO, Sept. 21, 2017 / PRNewswire/ - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company

Audentes Therapeutics RDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 22, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Audentes Therapeutics, Inc.

Audentes Therapeutics ESP

AUDENTES THERAPEUTICS, INC. 600 California Street, 17th Floor San Francisco, California 94108 August 22, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey Gabor Re: Audentes Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-219797) filed August 8, 2017 Ladies and Gentlemen: Re

Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

bold-ex99115.htm Exhibit 99.1 Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update - Audentes plans to initiate Phase 1/2 clinical trials for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome in the third quarter of 2017 - Audentes plans to report preliminary clinical data from Phase 1/2 studies of AT132 and

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 bold-8k20170810.htm EARNINGS RELEASE 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State

Lease, dated July 12, 2017, by and between the Registrant and Britannia Gateway II Limited Partnership

Exhibit 10.1 BRITANNIA GATEWAY BUSINESS PARK LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BRITANNIA GATEWAY II LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and AUDENTES THERAPEUTICS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION

Amended and Restated License Agreement, dated May 4, 2017, by and between the Registrant and Istituti Clinici Scientifici Maugeria S.p.A. SB (assignee of Fondazione Salvatore Maugeri).

Exhibit 10.2 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (“Agreement”) is effective as of September 26, 2014 (the “Effe

BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeuti

Third Amendment to Exclusive License and Collaboration Agreement, effective July 14, 2017, by and between the Registrant and The Trustees of the University of Pennsylvania.

Exhibit 10.3 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. THIRD AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This THIRD AMENDMENT (“Third Amendment”) is entered into as of July 14, 2017 (th

AUDENTES THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENT

EX-1.2 Exhibit 1.2 AUDENTES THERAPEUTICS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT August 8, 2017 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Audentes Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees

AUDENTES THERAPEUTICS, INC. , as Trustee Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 3 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTR

EX-4.5 Exhibit 4.5 AUDENTES THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 3 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5

FORM OF DEBT SECURITY

EX-4.4 3 d436569dex44.htm EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] AUDENTES THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF I

Power of Attorney

S-3 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2017 Registration No.

AUDENTES THERAPEUTICS, INC. Computation of Ratio of Earnings to Fixed Charges Year Ended December 31, Three Months Ended March 31, 2017 2013 2014 2015 2016 (in thousands) Earnings before fixed charges: Net loss $ (3,054 ) $ (10,819 ) $ (26,458 ) $ (5

EX-12.1 Exhibit 12.1 AUDENTES THERAPEUTICS, INC. Computation of Ratio of Earnings to Fixed Charges Year Ended December 31, Three Months Ended March 31, 2017 2013 2014 2015 2016 (in thousands) Earnings before fixed charges: Net loss $ (3,054 ) $ (10,819 ) $ (26,458 ) $ (59,668 ) $ (18,115 ) Fixed charges: Estimated interest expense within rental expense $ 10 $ 84 $ 490 $ 852 $ 233 Deficiency of ear

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

bold-8k20170712.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Inco

Audentes Therapeutics 8-K - JENNIFER JARRETT DIRECTOR APPOINTMENT (Current Report/Significant Event)

bold-8k20170612.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Inco

Audentes Therapeutics 8-K (Current Report/Significant Event)

bold-8k20170607.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incor

Audentes Therapeutics 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeut

Financial Statements and Exhibits, Results of Operations and Financial Condition

bold-8k20170511.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incor

Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

bold-ex99142.htm Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - INDs for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome are active - Strengthened balance sheet with a follow-on financing of $80.7 million in net proceeds - Preliminary clinical data from phase 1/2 studies of AT132 and AT3

EXECUTIVE EMPLOYMENT AGREEMENT

EX-10.01 2 d387386dex1001.htm EX-10.01 Exhibit 10.01 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and (the “Executive”). This Agreement is effective as of , 20 (the “Effective Date”). [This Agreement supersedes and replaces in its entirety the dated , between Executive and the Company.]1 In

Audentes Therapeutics 8-K (Current Report/Significant Event)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis

Audentes Therapeutics DEFA14A

bold-defa14a20170427.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission

Audentes Therapeutics DEF 14A

bold-def14a20170427.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission

Audentes Therapeutics AUDENTES THERAPEUTICS, INC. (Passive Acquisition of More Than 5% of Shares)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) April 18, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic

BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment

SC 13G/A 1 e616075sc13ga-at.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 0507

5,200,000 Shares Common Stock

424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-217225 and 333-217365 PROSPECTUS 5,200,000 Shares Common Stock We are offering 5,200,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol ?BOLD.? The last reported sale price of our common stock on The NASDAQ Global Market on April 18, 2017 was $15.19 per share. We are

Audentes Therapeutics S-1MEF

S-1MEF 1 d357125ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on April 18, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Audentes Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1606174 (State or other jurisdiction o

AUDENTES THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT

EX-1.1 2 d307713dex11.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT Dated: April [•], 2017 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT April [•], 2017 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC Piper Jaffra

Audentes Therapeutics S-1/A

S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 17, 2017 Registration No.

BOLD / Audentes Therapeutics, Inc. ESP

CORRESP 1 filename1.htm AUDENTES THERAPEUTICS, INC. 600 California Street, 17th Floor San Francisco, California 94108 April 17, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dorrie Yale Re: Audentes Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-217225) originally filed April 1

BOLD / Audentes Therapeutics, Inc. ESP

CORRESP April 17, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

LETTER

April 14, 2017 Matthew Patterson President and Chief Executive Officer Audentes Therapeutics, Inc.

Audentes Therapeutics RDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 11, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Audentes Therapeutics, Inc.

101 Montgomery Street • Suite 2650 • San Francisco • CA • 94104 • USA Location • You will work from the corporate headquarters located at 101 Montgomery Street, Suite 2650, SF, CA 94104. As the Company evolves, the exact location may change. Compensa

Offer Letter Agreement Exhibit 10.7 July 21, 2015 (As revised) VIA Email Dear Natalie, I am very pleased to extend an offer to join Audentes Therapeutics. We believe your experience, talent, and passion will make you a wonderful addition to our team. The following outlines the terms of our offer. Position ? Senior Vice President, Chief Operating Officer. This position is considered an exempt posit

101 Montgomery Street • Suite 2650 • San Francisco • CA • 94104 • USA Location • You will work from the corporate headquarters located at 101 Montgomery Street, Suite 2650, SF, CA 94104. As the Company evolves, the exact location may change. Compensa

EX-10.6 2 d307713dex106.htm OFFER LETTER AGREEMENT Exhibit 10.6 August 18, 2015 (As Revised) VIA Email Dear Tom, I am very pleased to extend an offer to join Audentes Therapeutics. We believe your experience, talent, and passion will make you a wonderful addition to our team. The following outlines the terms of our offer. Position • Senior Vice President, Chief Financial Officer. This position is

Audentes Therapeutics S-1

S-1 1 d307713ds1.htm S-1 Table of Contents As filed with the Securities and Exchange Commission on April 10, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2836 46-1606174 (State or other jur

Audentes Therapeutics 8-K (Current Report/Significant Event)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Comm

Second Amendment to Exclusive License and Collaboration Agreement, dated March 21, 2017, by and between the Registrant and The Trustees of the University of Pennsylvania.

EX-10.01 2 d270046dex1001.htm EX-10.01 EXHIBIT 10.01 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. SECOND AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT THIS SECOND AMENDMENT (“Second Amendmen

Audentes Therapeutics RDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 23, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Audentes Therapeutics, Inc.

Net Commercial Lease, effective June 1, 2017, by and between the Registrant and JCN Partners

EX-10.11 3 bold-ex10111123.htm EX-10.11 Exhibit 10.11 NET COMMERCIAL LEASE This Lease dated January 7, 2017, for reference purposes only, is by and between JCN PARTNERS, A CALIFORNIA LIMITED PARTNERSHIP (“Lessor”) and AUDENTES THERAPEUTICS, INC. a Delaware corporation (“Lessee”). IT IS HEREBY AGREED: Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the premises described in Pa

First Amendment to Office Lease, dated November 22, 2016, by and between the Registrant and MEPT 600 California Street LLC.

Exhibit 10.15 FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE (the “Amendment”) dated as of November 22, 2016 (the “Amendment Date”) is by and between MEPT 600 California Street LLC, a Delaware limited liability company (“Landlord”) and Audentes Therapeutics, Inc., a Delaware corporation (“Tenant”). BACKGROUND A. Landlord and Tenant entered into that certain Office Lease dated

Net Commercial Lease, effective May 1, 2017, by and between the Registrant and 546 Eccles Avenue, a California Limited Partnership

Exhibit 10.12 NET COMMERCIAL LEASE This Lease dated January 7, 2017, for reference purposes only, is by and between 546 ECCLES AVENUE, A CALIFORNIA LIMITED PARTNERSHIP (“Lessor”) and Audentes Therapeutics, Inc., a Delaware corporation (“Lessee”). IT IS HEREBY AGREED: Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the premises described in Paragraph 1 below for the term and s

Loan and Security Agreement, dated March 7, 2017, by and between the Registrant, each of its Qualified Subsidiaries, the several banks and other financial institutions party thereto, and Hercules Capital, Inc

Exhibit 10.25 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 7, 2017 and is entered into by and between AUDENTES THERAPEUTICS, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agree

First Amendment to Exclusive License and Collaboration Agreement, dated December 21, 2016, by and between the Registrant and The Trustees of the University of Pennsylvania.

EXHIBIT 10.24 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT THIS FIRST AMENDMENT (“First Amendment”) is entered into as of December 21, 201

First Amendment to Lease Agreement, effective May 1, 2017, by and between the Registrant and 546 Eccles Avenue, a California Limited Partnership.

EX-10.13 5 bold-ex1013741.htm EX-10.13 Exhibit 10.13 FIRST AMENDMENT TO LEASE AGREEMENT Property Address: 550-3 Eccles Avenue South San Francisco, California This First Amendment to Lease Agreement (this “Amendment”), dated for reference purposes January 13, 2017, is incorporated into and made a part of that certain Net Commercial Lease agreement (“Lease Agreement”) dated January 7, 2017 between 5

Warrant Agreement with Hercules Technology III, L.P. dated March 7, 2017

EXHIBIT 4.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS

Audentes Therapeutics 10-K (Annual Report)

bold-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-

Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

bold-ex9916.htm Exhibit 99.1 Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update - IND for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) submitted - IND for AT342 to treat Crigler-Najjar Syndrome active - Large scale, internal cGMP manufacturing established to support advancement of pipeline programs - Preliminary clinical data from

Audentes Therapeutics 8-K FY2016 EARNINGS RELEASE (Current Report/Significant Event)

bold-8k20170309.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Inco

Audentes Corporate Overview

EX-99.1 2 d355106dex991.htm EX-99.1 Exhibit 99.1 Audentes Corporate Overview Cowen and Company 37th Annual Health Care Conference March 7, 2017 Courageous Patients. Bold Effort. Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks

Regulation FD Disclosure, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Comm

BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

BOLD / Audentes Therapeutics, Inc. / 5AM VENTURES III, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number)

BOLD / Audentes Therapeutics, Inc. / Versant Side Fund IV, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2016 (Date of Ev

BOLD / Audentes Therapeutics, Inc. / OrbiMed Capital GP IV LLC - 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2016 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Comm

Courageous Patients.

EX-99.1 Courageous Patients. Bold Effort.? November 2016 Audentes Corporate Overview NASDAQ: BOLD Exhibit 99.1 AUDENTES THERAPEUTICS C 2 ORPORATE PRESENTATION Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, as

Audentes Therapeutics 8-K (Current Report/Significant Event)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2016 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (

Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Completed Initial Public Offering of 5.675 Million Shares of Common Stock, Completed Large-Scale Engineering Runs at Its Internal Manufacturing Facility,

EX-99.1 2 bold-ex9917.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Completed Initial Public Offering of 5.675 Million Shares of Common Stock, Completed Large-Scale Engineering Runs at Its Internal Manufacturing Facility, Commenced Enrollment in the INCEPTUS Clincal Assessment Study of XLMTM San Francisco, Calif., November